IWANAGA KAZUNORI

Affiliation and department：

Research field (1)： Clinical pharmacy

Research theme for competitive and other funds (2)：

2003 - 2005 Optimization of dosage regimen using a mechanism-based pharmacokinetic-pharmacodynamic modeling
1993 - 1994 Development of a new method for bioavailability assessment using a pharmacokineic/pharmacodynamic model

Papers (5)：

KAZUNORI IWANAGA. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach. J Clin Pharm Ther. 2018
KAZUNORI IWANAGA. Important issues in improving intestinal absorption of poorly soluble drugs. Progress in Drug Delivery System. 2016. 25. 5-10
Kazunori Iwanaga, Yutaka Kawabata, Makoto Miyazaki, Masawo Kakemi. Quantitative analysis of the effect of triglyceride alkyl-chain length on the partitioning of highly lipophilic compounds to the mesenteric lymph in intestinal cells. ARCHIVES OF PHARMACAL RESEARCH. 2014. 37. 7. 937-946
Makoto Miyazaki, Susumu Nakade, Kazunori Iwanaga, Masao Kakemi, Kazuhiro Morimoto. Estimation of Bioavailability of Salmon Calcitonin from the Hypocalcemic Effect in Rats (I): Pharmacokinetic-Pharmacodynamic Modeling Based on the Endogenous Ca Regulatory System. Drug Metabolism and Pharmacokinetics. 2003. 18. 6. 350-357
MIYAZAKI Makoto, SAWADA Shin-ichi, NISHIDE Takayoshi, MAEKAWA Chieko, MUKAI Haruko, IWANAGA Kazunori, MORIMOTO Kazuhiro, KAKEMI Masawo. ASSESSMENT OF BIOAVAILABILITY FROM PHARMACOLOGICAL RESPONSES. Drug Metabolism and Pharmacokinetics. 1999. 14. 126-127

MISC (1)：

MIYAZAKI Makoto, NAKADE Susumu, IWANAGA Kazunori, MORIMOTO Kazuhiro, KAKEMI Masao. Estimation of Bioavailability of Salmon Calcitonin from the Hypocalcemic Effect in Rats(II) : Effect of Protease Inhibitor on the Pharmacokinetic-Pharmacodynamic Relationship after Intranasal Administration. 2003. 18. 6. 358-364

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page